[Federal Register Volume 80, Number 18 (Wednesday, January 28, 2015)]
[Notices]
[Pages 4593-4594]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-01602]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Manufacturer of Controlled Substances Registration: Johnson 
Matthey, Inc.

ACTION: Notice of registration.

-----------------------------------------------------------------------

SUMMARY: Johnson Matthey, Inc. applied to be registered as a 
manufacturer of certain basic classes of controlled substances. The DEA 
grants Johnson Matthey, Inc. registration as a manufacturer of those 
controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated September 25, 2014, and 
published in the Federal Register on October 7, 2014, 79 FR 60498, 
Johnson Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte 
Drive, West Deptford, New Jersey 08066-1742, applied to be registered 
as a manufacturer of a certain basic class of controlled substance. No 
comments or objections were submitted to this notice.

[[Page 4594]]

    The Drug Enforcement Administration (DEA) has considered the 
factors in 21 U.S.C. 823(a) and determined that the registration of 
Johnson Matthey, Inc. to manufacture the basic classes of controlled 
substances is consistent with the public interest and with United 
States obligations under international treaties, conventions, or 
protocols in effect on May 1, 1971. The DEA investigated the company's 
maintenance of effective controls against diversion by inspecting and 
testing the company's physical security systems, verifying the 
company's compliance with state and local laws, and reviewing the 
company's background and history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above-named company is granted registration as a bulk 
manufacturer of marihuana (7360), a basic class of controlled substance 
listed in schedule I.
    In reference to drug code 7360, the company plans to manufacture a 
synthetic version cannabidiol in bulk for sale to its customers, who 
are final dosage form manufacturers. No other activity for this drug 
code is authorized for this registration.

    Dated: January 21, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-01602 Filed 1-27-15; 8:45 am]
BILLING CODE P